Exhibit 99.1

TFF TAC Data Presented at 44 th Annual ISHLT Meeting Late Breaking Abstract Oral Presentation April 13, 2024 BETTER DELIVERY, BETTER THERAPY | Powerful Drug Delivery Solutions NASDAQ: TFFP 1

Safe Harbor Statement SPECIAL NOTE REGARDING FORWARD - LOOKING STATEMENTS This document contains forward - looking statements concerning TFF Pharmaceuticals, Inc. (“TFF”, “TFF Pharmaceuticals”, the “Company,” “we,” “us,” and “our”). The words “believe,” “may,” “will,” “potentially,” “estimate,” “continue,” “anticipate,” “intend,” “could,” “would,” “project,” “plan,” “expect” and similar expressions that convey uncertainty of future events or outcomes are intended to identify forward - looking statements. These forward - looking statements include, but are not limited to, statements concerning the following: the benefits of our TFF platform; advancement of TFF TAC into potentially registration - enabling studies; TFF TAC’s substantial market opportunity; the expectation that the further data from the ongoing Phase 2 clinical trial for TFF TAC and will be consistent with the data readouts for each product candidate to date Those forward - looking statements involve known and unknown risks, uncertainties and other factors that could cause actual results to differ materially. Among those factors are: (i) the risk that the further data from the ongoing Phase 2 clinical trials for TFF TAC will not be favorably consistent with the initial data readouts, (ii) the risk that we may not be able to advance to registration - enabling studies for TFF TAC, (iii) success in early phases of pre - clinical and clinicals trials do not ensure later clinical trials will be successful; (iv) no drug product incorporating the TFF platform has received FDA pre - market approval or otherwise been incorporated into a commercial drug product, (v) the Company has no current agreements or understandings with any large pharmaceutical companies for the development of a drug product incorporating the TFF platform, (vi) the risk that the Company may not be able to obtain additional working capital with which to continue the Phase 2 clinical trials and or advance to the initiation of registration - enabling studies, for TFF TAC as and when needed and (vii) those other risks disclosed in the section “Risk Factors” included in the Company’s Annual Report on Form 10 - K filed with the SEC on March 28, 2024 and subsequently filed reports. TFF Pharmaceuticals cautions readers not to place undue reliance on any forward - looking statements. TFF Pharmaceuticals does not undertake, and specifically disclaims, any obligation to update or revise such statements to reflect new circumstances or unanticipated events as they occur, except as required by law. This document contains only basic information concerning TFF. Because it is a summary it does not contain all of the information you should consider before investing. Please refer to our reports and registration statements on file with the SEC for more comprehensive information concerning TFF Pharmaceuticals. 2

TFF TAC Clinical Data Update 3

Introduction • Successful lung transplant requires significant systemic immunosuppression, but this comes at the cost of significant systemic toxicity • Significant renal impairment is one such example (~25% @5yrs post - lung transplant) • Substituting oral tacrolimus with Tacrolimus Inhalation Powder (TFF TAC) may be able to still prevent lung allograft rejection while enabling lower systemic tacrolimus blood levels and potentially lessening renal toxicity 4

Inhalation Device for Lung Deposition • TFF TAC utilizes Thin Film Freezing particle engineering technology (TFF Pharmaceuticals) • Dry powder (3.2μm diam) in 1mg & 0.25mg capsules, delivered by a simple handheld inhaler* • 1 - 2 x daily 5 *FDA Cleared Plastiape RS00 monodose device

6 Phase 2 Study Design in Lung Transplant Patients Tac dosing • Design : Open label study of TFF TAC lung transplant recipients requiring reduced tacrolimus blood levels due to renal toxicity • Duration : Part A : 12 weeks; Part B : optional safety extension • Endpoints : Safety & tolerability, renal function, acute allograft rejection Screening Day 1 2 weeks Week 12 A: Treatment B: Optional open - label extension • Bronchoscopy & mucosal biopsy MMDx • Spirometry • Donor - derived cell - free DNA assay • Donor Specific Antibody (DSA) • CT chest TFF TAC • Bronchoscopy & mucosal biopsy MMDx • Spirometry • Donor - derived cell - free DNA assay • Donor Specific Antibody (DSA) • CT chest Oral Tacrolimus TFF TAC MMDx: Molecular Microscope Diagnostic System

7 Phase 2 Study Inclusion Criteria • >18 years • >6 months post bilateral lung transplant • Triple immunosuppression • Stable (infection/rejection/reflux) • >40% predicted FEV1 • Creatinine >124µmol/L or eGFR < 45 mL/min/1.73m 2 * • Non - smoker FEV1: Forced Expiratory Volume in One Second eGFR: Estimated Glomerular Filtration Rate *GFR<45mL/min/1.73m 2 is consistent with moderate to severe chronic kidney disease

8 Baseline Characteristics and Demographics Disposition Time on TFF TAC (weeks) Years with kidney disease CLAD Years since transplant Race Sex Age (years) Patient Chose to proceed to Part B 49 5 No 9 W M 73 Pt 1 Chose to proceed to Part B 40 6 No 8 W F 73 Pt 2 Chose to proceed to Part B 33 4 No 5 W M 68 Pt 3 Chose to proceed to Part B 20 2.5 No 3 W F 67 Pt 4 Still in Part A 12 2.5 No 3 W M 64 Pt 5 Still in Part A 9 7 No 23 W F 52 Pt 6 Still in Part A 6 N/A No 0.75 W F 41 Pt 7 Still in Part A 5 2 No 1.25 NH M 56 Pt 8 CLAD: Chronic Lung Allograft Dysfunction W: white ; F: female; M: male; NH: Native Hawaiian N/A: not available Data is from TFF - T2 - 001 pre - database lock; Data cut off date: 3/25/24

Data Suggest TFF TAC Prevents Rejection at a Fraction Of Oral Tacrolimus Dose With Reduced Systemic Exposures Reduction in systemic exposures to 2/3 are expected to decrease toxicities Trough TFF TAC/Oral Tac Blood Level Trough TFF TAC: Oral Tac Blood Level (ng/mL) Stable TFF TAC/Oral Tac Dose Stable* TFF TAC: Oral Tac Dose (mg) Patient ~1/2 2.4 : 5.6 1/7 0.75 : 5 Pt 1 ~1/2 2.2 : 3.9 1/4 0.25 : 1 Pt 2 ~2/3 3.2 : 4.6 1/11 0.5 : 5.5 Pt 3 ~1 3.8 : 4.5 1/4 0.5 : 2 Pt 4 ~1/2 2.6 : 5.1 1/8 0.375 : 3 Pt 5 ~1 4.0 : 3.8 1/4 0.75 : 3 Pt 6 ~1 5.3 : 5.4 1/9 1.5 : 13 Pt 7 ~1/4 2.3 : 8.9 1/12 0.5 : 6 Pt 8 ~2/3 (66%) ~1/6 (17%) Average 9 Data is from TFF - T2 - 001 pre - database lock; Data cut off date: 3/8/24 *Stable dose is defined as no change in dose level or frequency for 3 consecutive weeks

Blood Trough Levels 16 14 12 10 8 6 4 2 0 TFF TAC Blood Level (ng/mL) 10 Data is from TFF - T2 - 001 pre - database lock; Data cut off date: 3/8/24 Pt 1 Pt 2 Pt 3 Pt 4 Pt 5 Pt 6 Pt 7 Pt 8 TFF TAC dose is reduced over time to protect the kidneys resulting in diminished tacrolimus blood levels; no acute rejection despite decrease in TFF TAC dose and systemic exposures

Lower Doses of TFF TAC Result in Diminished Systemic Exposures and Less Pharmacokinetic Variability with Chronic Dosing Mean Tacrolimus in Blood - 6hr AUC Curve Day 1 doses: Patient 1=1. 5mg Patient 2=1.5 mg Patient 3=0.75 mg Day 85 doses: Patient 1=1 mg Patient 2=0.25 mg Patient 3=0.5 mg Trough Tacrolimus in Blood AUC: Area Under the Concentration - Time 11 Data is from TFF - T2 - 001 pre - database lock; Data cut off date: 3/8/24 Reduced pharmacokinetic variability is predicted to decrease risk of rejection and toxicities

Renal Function Maintained 60 55 50 45 40 35 30 25 20 15 10 eGFR (mL/min/1.73m 2 ) 12 Data is from TFF - T2 - 001 pre - database lock; Data cut off date: 3/8/24 Pt 1 Pt 2 Pt 3 Pt 4 Pt 5 Pt 6 Pt 7 Pt 8

Normalization of Rejection - Related Gene Expression Following Transition From Oral Tacrolimus to TFF TAC Gene Expression Analysis Using MMDx • No gene expression evidence of rejection in 4/4 patients with available gene expression data on endobronchial biopsies: • Rejection - related genes normalized in 3/3 patients with abnormal expression of rejection - related genes at baseline while on oral tacrolimus • Rejection - related genes remained normal in one patient with normal expression at baseline 13 Data is from TFF - T2 - 001 pre - database lock; Data cut off date: 3/8/24 MMDx: Molecular Microscope Diagnostic System

Patient 1: MMDx Gene Expression Analysis Following Transition from Oral Tacrolimus to TFF TAC 0.61 0.31 Normal 0 0.23 Rejection 0.09 0.14 CLAD Biopsy 1: Oral Tac Day 0 Biopsy 2: TFF TAC Day 85 = Patient 1 Result = Patient 1 Result 14 Data is from TFF - T2 - 001 pre - database lock; Data cut off date: 3/8/24 ; Halloran et al. American Journal of Transplant, 2020; Halloran et al. Journal of Heart and Lung Transplantation, 2019 Patient 1’s gene expression shifted from a profile consistent with rejection and CLAD to a more normal profile upon transition to TFF TAC MMDx: Molecular Microscope Diagnostic System

MMDx Analysis: Increase in Normal Gene Expression TFF TAC Day 85 Normalness Rejection Late CLAD Oral Tacrolimus Day 0 Normalness Rejection Late CLAD 15 Data is from TFF - T2 - 001 pre - database lock; Data cut off date: 3/8/24

Number of Abnormally Expressed Genes Decreased on TFF TAC Day 85 Day 0 Day 85 Day 0 Day 85 Day 0 Day 85 Day 0 Gene Sets Normal Normal Normal Normal Normal Normal Normal Normal Endothelium Related Normal Slightly Abnormal Normal Normal Slightly Abnormal Abnormal Slightly Abnormal Abnormal Rejection Related Normal Slightly Abnormal Normal Normal Normal Slightly Abnormal Normal Abnormal Normal Abnormal Normal Normal Slightly Abnormal Slightly Abnormal Normal Abnormal Normal Slightly Abnormal Normal Normal Normal Slightly Abnormal Normal Abnormal Normal Normal Normal Normal Normal Normal Normal Abnormal Slightly Abnormal Slightly Abnormal Normal Normal Slightly Abnormal Slightly Abnormal Slightly Abnormal Abnormal Normal Normal Normal Normal Normal Normal Normal Normal Normal Normal Normal Normal Slightly Abnormal Normal Abnormal Slightly Abnormal Injury Related Normal Normal Normal Slightly Abnormal Normal Normal Normal Slightly Abnormal Slightly Abnormal Normal Normal Normal Normal Normal Normal Abnormal Late Atrophy/Scarring Related Abnormal Slightly Abnormal Normal Normal Normal Normal Slightly Abnormal Slightly Abnormal Normal Normal Normal Normal Normal Normal Normal Normal Other Normal Normal Normal Normal Normal Normal Normal Normal Abnormal Normal Abnormal Abnormal Abnormal Abnormal Abnormal Abnormal 4 6 1 2 5 6 5 11 Abnormal Count: 16 Data is from TFF - T2 - 001 pre - database lock; Data cut off date: 3/8/24 Patient 1 Patient 2 Patient 3 Patient 4

Lung Function Remained Stable on TFF TAC 140 120 100 80 60 40 20 0 FEV 1 % predicted 17 Data is from TFF - T2 - 001 pre - database lock; Data cut off date: 3/8/24 Pt 1 Pt 2 Pt 3 Pt 4 Pt 5 Pt 6 Pt 7 Pt 8

Adverse Events • Infections • COVID x4 • Complicated x1 with decreased lung FEV 1 • Lower Respiratory Tract Infection x1 picornavirus • Complicated by pleurisy, coronary angiogram pseudoaneurysm, atrial fibrillation, oral candida • Headache x2, tremor x1 • Increased creatinine x3 • Ultimately recovered in 2/3, recovering in 1/3 18 Data is from TFF - T2 - 001 pre - database lock; Data cut off date: 3/8/24 FEV1: Forced Expiratory Volume in One Second The adverse event profile of TFF TAC is compatible with that of oral tacrolimus

Summary Efficacy • Successful transition of 8/8 from oral tac to TFF TAC • No evidence of acute rejection • No signs and symptoms suggestive of acute rejection • No use of pulse corticosteroids for treatment of rejection • No spirometry deterioration suggestive of acute rejection • No CXR findings suggestive of acute rejection • No mucosal biopsy evidence of acute rejection CXR: Chest X - Ray Data is from TFF - T2 - 001 pre - database lock; Data cut off date: 3/8/24 19 Safety • No mortality • No TFF TAC discontinuation due to an AE • Majority of AEs were < Grade 2 severity • Maintenance of lung function • Maintenance of renal function Tolerability • Simple to use • 1 - 2 times daily • Stable levels • 4/4 completing Part A continued on TFF TAC in Part B

Conclusion • TFF TAC shows promise as a simple, safe lung transplant immunosuppressant • Emerging experience, biomarker levels, gene expression & further immunological assessment will prove key in potentially enabling us to evaluate if even lower blood tac levels are possible • The current study may be initiating changes to tac dosing too late to influence renal deterioration in some transplant recipients • If current trends continue, then TFF TAC may be indicated earlier post - lung transplant – before systemic damage (e . g . renal impairment) becomes established 20

THANK YOU 21